Year-Long Study Shows Brain Stenting Has Long-Term Effectiveness

I don't think a 8.5% stroke and death rate is effective. What would you do if your doctor said you have an 8.5% chance of dying or having another stroke from the stent procedure and 2.6% in the first days? 

Don't listen to me, I'm not medically trained and I don't have a Dr. in front of my name.

But I'd rather my doctor told me how much watermelon juice to drink.

Watermelon juice reverses hardening of the arteries  Nov. 2011

 

 The latest here:

Year-Long Study Shows Brain Stenting Has Long-Term Effectiveness

By Alex Morrisson

LOS ANGELES -- February 24, 2020 -- A long-term follow-up study appears to indicate that the Wingspan brain stent -- aimed at preventing recurrent strokes -- is safe and effective when used on-label, according to a study presented here at the 2020 International Stroke Conference (ISC).

Patients who received the Wingspan stent for intracranial atherosclerotic disease experienced a 1-year stroke and death rate of 8.5%.
“This trial is unique because prior studies included off-label patients,” said Michael J. Alexander, MD, Cedars-Sinai Medical Center, Los Angeles, California. “This is the largest intracranial stent trial for atherosclerotic disease performed according to the FDA [US Food and Drug Administration] indication for the Wingspan stent. The stroke and death rates were substantially lower than the 1-year rate of 20% in the stenting arm of the SAMMPRIS trial and slightly better than the 12.2% stroke and death rate in the medical arm of SAMMPRIS.”

The Stenting and Aggressive Medical Management for the Prevention of Recurrent Ischemic Stroke (SAMMPRIS) was a large multicentre study comparing the 2 methods of stroke prevention. In the follow-up study, the Wingspan One-year Vascular Imaging, Events and Neurologic Outcomes (WOVEN) study showed a low 2.6% stroke and death rate within the first few days of the procedure in patients who received the Wingspan stent.(Not low enough.)

A third study -- WEAVE -- was mandated by the FDA to assess the periprocedural safety of the Wingspan Stent system in the treatment of symptomatic intracranial atherosclerotic disease. It was conducted at 16 US centres and followed 152 patients. Enrolling sites performed chart and image reviews of patients who were stented with Wingspan under its strict on-label usage. Data of subsequent strokes and deaths were collected with respect to time from stenting and medications at the time of the index event. Follow-up imaging was assessed for incidence and severity of in-stent stenosis and the follow-up management of these patients.

At 1-year, the stroke and death rate was 8.5% for patients who received the Wingspan stent.

“The long-term results are important to determine if safer stenting practices and lower complication rates from the treatment itself resulted in improved patient outcomes at 1 year,” said Dr. Alexander. “Intracranial stenting could provide an alternative when medical therapy and other treatments have been unsuccessful.”

The patients in the trials were treated with Wingspan if it was determined that their ischaemic stroke was caused by a blockage of 70% to 99% of an intracranial artery.

ISC is sponsored by the American Heart Association and the American Stroke Association.

[Presentation title: The Woven Study: Wingspan One-Year Vascular Imaging, Events, and Neurologic Outcomes. Abstract LB4]